Andreas Jakob
About
Andreas Jakob is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Andreas Jakob has authored 21 papers receiving a total of 177 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in Andreas Jakob's work include Bone health and treatments (4 papers), Cancer Diagnosis and Treatment (4 papers) and Renal cell carcinoma treatment (3 papers). Andreas Jakob is often cited by papers focused on Bone health and treatments (4 papers), Cancer Diagnosis and Treatment (4 papers) and Renal cell carcinoma treatment (3 papers). Andreas Jakob collaborates with scholars based in Germany, Switzerland and Austria. Andreas Jakob's co-authors include Carsten Bokemeyer, Lothar Kanz, Jürgen Schulte‐Mönting, Carsten Grüllich, Jürgen Finke, Hartmut Bertz, Marius Horger, Jens Huober, Dirk Behringer and Christoph Heining and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Medical Internet Research.
In The Last Decade
Andreas Jakob
20 papers receiving 172 citations
Peers
Andreas Jakob
Barbara Sosnowska‐Pasiarska Poland
Luke Mountjoy United States
Konstantinos Christofyllakis Germany
Maria Anna Siciliano Italy
Ali Abdulnabi Suwaidan United Kingdom
Tamara A. Sussman United States
H. Riess Germany
Benjamin Powers United States
Monica Castelli Italy
Hirotsugu Ariizumi Japan
Citations per year, relative to Andreas Jakob Andreas Jakob (= 1×)
peers
Barbara Sosnowska‐Pasiarska
Countries citing papers authored by Andreas Jakob
Since
Specialization
Citations
This map shows the geographic impact of Andreas Jakob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Jakob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Jakob more than expected).
Fields of papers citing papers by Andreas Jakob
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Andreas Jakob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Jakob. The network helps show where Andreas Jakob may publish in the future.
Co-authorship network of co-authors of Andreas Jakob
This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Jakob. A scholar is included among the top collaborators of Andreas Jakob based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Jakob. Andreas Jakob is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Witschel, Hans Friedrich, Stefanie Hayoz, Ulf Petrausch, et al.. (2025). Unsupervised dynamic ePRO reporting of immunotherapy related symptoms in cancer patients. Oncology. 1–13.
2.
Mark, Michael, Alfonso Mora, Thomas Winder, et al.. (2024). Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study. Bone Reports. 22. 101794–101794.
3.
Petrausch, Ulf, Alfonso Mora, Thomas Winder, et al.. (2023). Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.. Journal of Clinical Oncology. 41(16_suppl). 6619–6619.
4.
Jakob, Andreas, Arnd Nusch, Roland Schnell, et al.. (2022). Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study. Journal of bone oncology. 33. 100420–100420.
5.
Trojan, Andreas, Christoph Thomssen, Achim Rody, et al.. (2021). The Effect of Collaborative Reviews of Electronic Patient-Reported Outcomes on the Congruence of Patient- and Clinician-Reported Toxicity in Cancer Patients Receiving Systemic Therapy: Prospective, Multicenter, Observational Clinical Trial. Journal of Medical Internet Research. 23(8). e29271–e29271.
6.
Wieshammer, Siegfried, Jens Dreyhaupt, Dirk Müller, Felix Momm, & Andreas Jakob. (2016). Limitations of N-Terminal Pro-B-Type Natriuretic Peptide in the Diagnosis of Heart Disease among Cancer Patients Who Present with Cardiac or Pulmonary Symptoms. Oncology. 90(3). 143–150.
7.
Wieshammer, Siegfried, Jens Dreyhaupt, Dirk Müller, Felix Momm, & Andreas Jakob. (2016). Venous thromboembolism and persistent pulmonary hypertension in cancer patients: a cross-sectional study. Thrombosis Journal. 14(1). 3–3.
8.
Müller, Volkmar, Andreas Jakob, Bahriye Aktas, et al.. (2016). Abstract P4-13-26: Efficacy, safety, and treatment decision-making in the AVANTI German observational study of first-line bevacizumab (BEV)-containing therapy for locally advanced, recurrent, or metastatic breast cancer (aBC). Cancer Research. 76(4_Supplement). P4–13.
9.
Bergmann, Lothar, Peter J. Goebell, Manfred Kindler, et al.. (2013). Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study. Oncology Research and Treatment. 36(3). 95–100.
10.
Wieshammer, Siegfried, Jens Dreyhaupt, Dirk Müller, et al.. (2013). Cardiotoxicity and Cancer Therapy: Treatment-Related Cardiac Morbidity in Patients Presenting with Symptoms Suggestive of Heart or Lung Disease. Oncology. 85(3). 137–144.
11.
Hadji, Peyman, Matthias Frank, Andreas Jakob, & J. W. Siebers. (2013). Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohort. Journal of bone oncology. 2(1). 2–10.
12.
Schneeweiß, Andreas, et al.. (2013). Abstract P4-14-04: AVANTI: A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer. Cancer Research. 73(24_Supplement). P4–14.
13.
Bergmann, Lothar, Peter J. Goebell, Manfred Kindler, et al.. (2012). Updated results of a prospective noninterventional study of everolimus after use of 1 VEGFR-TKI.. Journal of Clinical Oncology. 30(15_suppl). e15044–e15044.
14.
Bergmann, Lars, Manfred Kindler, Thomas Koepke, et al.. (2011). A noninterventional study of everolimus in metastatic renal cell cancer after use of one VEGFR-TKI: Results of a preplanned interim analysis of a prospective study.. Journal of Clinical Oncology. 29(15_suppl). 4552–4552.
15.
Jakob, Andreas, et al.. (2010). Abstract P5-13-04: Use of Bisphosphonates in the Adjuvant Setting for Breast Cancer — A More Than 10 Years Single Centre Experience. Cancer Research. 70(24_Supplement). P5–13.
16.
Heining, Christoph, Alexandros Spyridonidis, Jürgen Schulte‐Mönting, et al.. (2007). Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. Bone Marrow Transplantation. 39(10). 613–622.
17.
Jakob, Andreas, et al.. (2006). Retrospective Analysis of CD38 Expression in 102 Patients with B-CLL with a Maximum Follow-Up of 18 Years: Incidence and Prognostic Significance. Oncology Research and Treatment. 29(10). 437–441.
18.
Hartmann, J. T., Karin Oechsle, Jens Huober, et al.. (2005). An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Investigational New Drugs. 24(3). 249–253.
19.
Jakob, Andreas, Carsten Bokemeyer, Stefan Knop, et al.. (2002). Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation—a phase II study. Anti-Cancer Drugs. 13(4). 405–410.
20.
Jakob, Andreas, et al.. (1958). [Our results with radio strontium and radio yttrium irradiation of hemangioma and nevus flammeus].. PubMed. 107(4). 532–6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Barbara Sosnowska‐Pasiarska Breakdown of academic impact, for papers by Luke Mountjoy Breakdown of academic impact, for papers by Konstantinos Christofyllakis Breakdown of academic impact, for papers by Maria Anna Siciliano Breakdown of academic impact, for papers by Ali Abdulnabi Suwaidan Breakdown of academic impact, for papers by Tamara A. Sussman Breakdown of academic impact, for papers by H. Riess Breakdown of academic impact, for papers by Benjamin Powers Breakdown of academic impact, for papers by Monica Castelli Breakdown of academic impact, for papers by Hirotsugu Ariizumi